Alnylam Pharmaceuticals
ALNY
#539
Rank
S$54.10 B
Marketcap
S$407.92
Share price
-0.40%
Change (1 day)
12.47%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): S$2.30

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is S$2.32. In 2023 the company made an earnings per share (EPS) of S-$4.56 an increase over its 2022 EPS that were of S-$11.99.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$2.30
2023S-$4.56-62%
2022S-$11.9929.03%
2021S-$9.29-3.36%
2020S-$9.61-8.48%
2019S-$10.507.67%
2018S-$9.7639.74%
2017S-$6.9812.94%
2016S-$6.1838.84%
2015S-$4.45-32.88%
2014S-$6.63259.44%
2013S-$1.85-31.25%
2012S-$2.68

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
S$9.29 300.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
S$2.67 14.73%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
S$55.65 2,295.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
S-$3.54-252.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
S-$0.94-140.56%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
S-$0.31-113.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
S$1.60-31.11%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
S$0.45-80.56%๐Ÿ‡บ๐Ÿ‡ธ USA